Interpretation of PSA Level 0.58 ug/L
A PSA level of 0.58 ug/L (0.58 ng/mL) is well within normal range and indicates very low risk for prostate cancer. This value is significantly below the traditional threshold of 4.0 ng/mL used for prostate cancer screening and even below the more conservative threshold of 2.5 ng/mL recommended in some guidelines 1.
Risk Assessment Based on PSA Value
- PSA 0.58 ng/mL falls into the lowest risk category:
Clinical Implications
Follow-up Recommendations
- Routine screening interval: With this low PSA value, screening can safely be extended to every 2 years rather than annually 1
No Need for Immediate Additional Testing
- At this PSA level:
- No indication for prostate biopsy
- No need for additional imaging studies
- No need for more frequent PSA monitoring
Context of PSA Interpretation
Age-Related Considerations
- PSA levels typically increase with age due to benign prostatic hyperplasia
- A value of 0.58 ng/mL would be considered very low regardless of age
- Even using age-specific reference ranges, this value would be well within normal limits for any age group 1
Other Factors That Can Affect PSA Levels
- Medications like finasteride or dutasteride can lower PSA values by approximately 50% 3
- Recent prostatitis, ejaculation, urinary retention, or prostate manipulation may temporarily elevate PSA levels 3
- Certain physical activities (bicycle riding, horseback riding) can transiently increase PSA 3
Post-Treatment PSA Interpretation (If Applicable)
If this PSA value is being measured after treatment for prostate cancer:
After radical prostatectomy:
- PSA should be undetectable (<0.1 ng/mL)
- A value of 0.58 ng/mL would be concerning for biochemical recurrence 1
After radiation therapy:
- PSA should reach a nadir and remain stable
- Biochemical recurrence is defined as PSA ≥2.0 ng/mL above nadir 1
Conclusion
This PSA value of 0.58 ng/mL represents a very low risk for prostate cancer in a screening context. Continued routine screening at extended intervals (every 2 years) is appropriate unless other risk factors are present, such as family history of prostate cancer or African American ethnicity 1.